Helio Health Group Announces Strategic Minority Investment from WestView Capital Partners to Accelerate Growth
June 3rd, 2026
Helio Health Group Announces Strategic Minority Investment from WestView Capital Partners to Accelerate Growth
Investment will support Helio to continue building AI-enabled solutions and specialized managed services across Compliance, Government Pricing, and Commercial areas
Helio represents WestView’s eighth investment in life sciences services and technology, reflecting the firm’s strong conviction in the sector and deep domain expertise
Morristown, NJ – June 3, 2026 – Helio Health Group, LLC (“HELIO” or the “Company”), a specialized expert-driven Artificial Intelligence (AI) company focused on the life sciences industry, today announced that it has received a strategic minority investment from WestView Capital Partners (“WestView”), a Boston-based growth equity firm focused exclusively on partnering with middle market growth companies.
The investment will provide HELIO with additional capital and strategic support to accelerate its next phase of growth, including expanding its team, deepening its capabilities across life sciences compliance, government pricing, and commercialization sectors, and continuing to invest in AI-enabled platforms that help clients operate more efficiently and intelligently.
Founded to serve the increasingly complex needs of pharmaceutical, biotechnology, and broader life sciences companies, HELIO provides deep expertise across the industry. The Company has built a differentiated model that combines deep industry expertise with practical execution and advanced AI capabilities and is ready to apply that expertise in Commercial markets such as Market Access support.
“This partnership represents an important milestone for HELIO,” said Manny Tzavlakis, Managing Partner of Helio Health Group. “We have always focused on building a company that delivers exceptional value to life sciences clients through expertise, responsiveness, and innovation. With WestView Capital Partners as a strategic partner, we will have additional resources to scale our AI assets, invest in new resources, and continue building technology-enabled solutions that address our clients’ most important challenges.”
As part of the transaction, HELIO’s existing leadership team of Marci Juneau, John Poulin and Manny Tzavlakis will continue to lead the business and retain significant ownership in the Company. The investment is structured as a minority partnership, allowing HELIO to preserve its entrepreneurial culture while gaining access to additional capital, operational resources, and strategic guidance.
“HELIO has established itself as a trusted partner to life sciences organizations navigating complex commercial, regulatory, and operational environments,” said Greg Thomas, Partner at WestView Capital Partners. “We are excited to support the HELIO team as they continue to expand their capabilities, invest in technology, and continue building AI tools serving the life sciences industry.”
The partnership is expected to support HELIO’s growth initiatives, including selective hiring, expansion of service lines, continued development of AI-enabled offerings, and potential strategic acquisitions that complement the Company’s existing expertise.
Financial terms of the transaction were not disclosed. Simpson Thacher & Bartlett LLP served as legal counsel to HELIO, and Latham & Watkins LLP served as legal counsel to WestView Capital Partners, in the transaction.
About Helio Health Group, LLC
Helio Health Group, LLC is an expert-driven AI and technology-enabled services firm that helps pharmaceutical, biotechnology, and healthcare companies address complex compliance, government pricing, commercial contracting and operational challenges. HELIO combines senior industry expertise, practical execution, and advanced AI-enabled capabilities to help clients improve performance, reduce risk, and scale with confidence. For more information, please visit Heliogrp.com.
About WestView Capital Partners
WestView Capital Partners, a Boston-based growth equity firm focused exclusively on middle market growth companies, manages $2.7 billion in capital across five funds. WestView partners with existing management teams to sponsor minority and majority recapitalizations, growth, and consolidation transactions in several sectors, including healthcare technology and outsourcing, business services, software and IT services, and growth industrial. For more information, please visit WVCapital.com.
Media Contact
Steven Moore
Chief Commercial Officer
Helio Health Group, LLC
EMAIL: smoore@heliogrp.com
PHONE: 315-209-0262